News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,063 Results
Type
Article (38989)
Company Profile (277)
Press Release (644797)
Section
Business (203838)
Career Advice (1987)
Deals (35358)
Drug Delivery (84)
Drug Development (80773)
Employer Resources (168)
FDA (16085)
Job Trends (14800)
News (344485)
Policy (32432)
Tag
Academia (2530)
Alliances (49041)
Alzheimer's disease (1218)
Approvals (16005)
Artificial intelligence (122)
Bankruptcy (352)
Best Places to Work (11489)
Biotechnology (196)
Breast cancer (111)
Cancer (968)
Cardiovascular disease (82)
Career advice (1657)
Cell therapy (209)
Clinical research (63999)
Collaboration (339)
Compensation (173)
COVID-19 (2524)
C-suite (85)
Data (940)
Diabetes (140)
Diagnostics (6113)
Earnings (84489)
Employer resources (146)
Events (109114)
Executive appointments (256)
FDA (16550)
Funding (301)
Gene therapy (153)
GLP-1 (566)
Government (4321)
Healthcare (18659)
Infectious disease (2603)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16275)
Job creations (3623)
Job search strategy (1415)
Layoffs (409)
Legal (7849)
Lung cancer (158)
Manufacturing (159)
Medical device (13152)
Medtech (13157)
Mergers & acquisitions (19120)
Metabolic disorders (375)
Neuroscience (1462)
NextGen Class of 2024 (6497)
Non-profit (4463)
Northern California (1304)
Obesity (223)
Opinion (176)
Patents (96)
People (56158)
Phase I (19867)
Phase II (28178)
Phase III (21032)
Pipeline (320)
Postmarket research (2553)
Preclinical (8452)
Radiopharmaceuticals (234)
Rare diseases (189)
Real estate (5888)
Regulatory (21460)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1163)
Startups (3560)
United States (12285)
Vaccines (542)
Weight loss (163)
Date
Today (232)
Last 7 days (1068)
Last 30 days (3276)
Last 365 days (35456)
2024 (31168)
2023 (40074)
2022 (51174)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28571)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (188)
Asia (37044)
Australia (6040)
California (2936)
Canada (1207)
China (224)
Colorado (127)
Connecticut (131)
Europe (79307)
Florida (415)
Georgia (104)
Illinois (320)
Indiana (187)
Kansas (96)
Maryland (543)
Massachusetts (2374)
Michigan (146)
Minnesota (257)
New Jersey (868)
New York (876)
North Carolina (674)
Northern California (1304)
Ohio (129)
Pennsylvania (780)
South America (1091)
Southern California (1163)
Texas (404)
Utah (84)
Washington State (335)
684,063 Results for "oragenics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Oragenics, Inc. Announces Pricing of Public Offering
Oragenics, Inc. today announced that it has entered into a placement agency agreement for the purchase and sale of 1,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per share.
June 25, 2024
·
3 min read
BioMidwest
Oragenics, Inc. Announces Proposed Public Offering - June 24, 2024
Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced that it intends to offer and sell shares of its common stock.
June 24, 2024
·
3 min read
BioMidwest
Oragenics, Inc. Announces Closing of Public Offering - June 26, 2024
Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share.
June 26, 2024
·
3 min read
Deals
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
Oragenics, Inc. today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated June 18, 2024, notifying the Company that it has accepted the Company’s plan to regain compliance with NYSE American’s continued listing standards.
June 20, 2024
·
2 min read
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
Oragenics, Inc. today announced that the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET.
May 17, 2024
·
3 min read
Drug Development
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
Oragenics, Inc. today announced an update on the company and its drug development program. Oragenics is designing an upcoming Phase II clinical trial conducted in acute and emergency departments.
May 16, 2024
·
5 min read
Press Releases
Oragenics, Inc. Announces Pricing of Public Offering
September 4, 2024
·
4 min read
Press Releases
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
October 8, 2024
·
4 min read
Press Releases
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
October 9, 2024
·
7 min read
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
Oragenics, Inc. today announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury.
June 27, 2024
·
4 min read
1 of 68,407
Next
